does noom glp 1 work upgrades GLP-1 weight management app features as digital therapeutics gain US market traction Noom’s New Microdose GLP-1 Program

EBID (RR: 3.3, 95%CI: 1.6, 6.9) and semaglutide (RR: 4.6, 95%CI: 1.6, 10.0) significantly increased the risk of hypoglycemia while the other GLP-1 RAs showed no statistically significant difference in hypoglycemia compared to placebo (S13 and S14 Figs)

Medications like semaglutide and tirzepatide (known by commercial names like Ozempic, Wegovy, Zepbound and Mounjaro) that target GLP-1 receptors have revolutionized the treatment of diabetes and obesity, offering dramatic weight loss and surprising benefits for other chronic conditions

Dehydration significantly contributes to fatigue and can be subtle in onset

The patient had no gastrointestinal symptoms on the day of the procedure

With 12% of Americans using GLP-1s a figure thats only expected to grow as the medications become more available and affordable the food and beverage industry has begun to feel the impact, which is hitting some categories harder than others